Article

BioMedicine

, 4:3

First online:

Open Access This content is freely available online to anyone, anywhere at any time.

Contribution of personalized Cyclin D1 genotype to triple negative breast cancer risk

  • Liang-Chih LiuAffiliated withTerry Fox Cancer Research Laboratory, China Medical University Hospital
  • , Chen-Hsien SuAffiliated withTerry Fox Cancer Research Laboratory, China Medical University HospitalGraduate Institute of Clinical Medical Science, China Medical University
  • , Hwei-Chung WangAffiliated withTerry Fox Cancer Research Laboratory, China Medical University Hospital
  • , Wen-Shin ChangAffiliated withTerry Fox Cancer Research Laboratory, China Medical University HospitalGraduate Institute of Clinical Medical Science, China Medical University
  • , Chia-Wen TsaiAffiliated withTerry Fox Cancer Research Laboratory, China Medical University HospitalGraduate Institute of Basic Medical Science, China Medical University
  • , Ming-Chei MaaAffiliated withGraduate Institute of Basic Medical Science, China Medical University
  • , Chang-Hai TsaiAffiliated withTerry Fox Cancer Research Laboratory, China Medical University Hospital
  • , Fuu-Jen TsaiAffiliated withDepartment of Medical Research, China Medical University Hospital
  • , Da-Tian BauAffiliated withTerry Fox Cancer Research Laboratory, China Medical University HospitalGraduate Institute of Basic Medical Science, China Medical UniversityGraduate Institute of Clinical Medical Science, China Medical University Email author 

Abstract

Aim: Cell cycle regulator cyclin D1 (CCND1) is a pivotal regulator for G1/S phase transition, playing a critical part in initiation of carcinogenesis. Triple negative breast cancer comprises a very heterogeneous group of cancer cells, but little is known about what is wrong in the genome of these patients. This study investigated contribution of CCND1 genotype to individual triple negative breast cancer susceptibility.

Materials: In all, 2464 native Taiwan subjects consist of 1232 breast cancer cases and 1232 controls were enrolled in a hospital-based, case-control study. CCND1 A870G (rs9344) genotyping was analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Risk-stratified analyses correlated genotype and age-related characteristics of breast cancer subgroups.

Results: No significant difference was found between patient and control groups in distribution of genotypic and allelic frequencies in CCND1 genotype, yet CCND1 A870G (rs9344) GG genotype was far less prevalent in breast cancer patients younger than 55 years (OR=0.62, 95%CI=0.43–0.89, P=0.0362), with first menarche earlier than 12.2 years (OR=0.61, 95% CI=0.42–0.87, P=0.0241), with menopause earlier than 49.0 years (OR=0.57, 95%CI=0.39–0.82, P=0.0093), or showing triple-negative breast cancer (OR=0.28, 95%CI=0.13–0.62, P=0.0006). Such valuable findings suggest CCND1 A870G (rs9344) as a predictive marker for triple negative breast cancer in Taiwanese women; the authors sincerely hope these help us fight the toughest subtype in clinical management.

Keywords

Cyclin D1 Genotype Triple negative breast cancer